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Hypertension has been related to the establishment of brain damage and is the 
main risk factor for the development of cerebrovascular disease. Abnormal regulation 
of cholinergic neurotransmission might contribute to cognitive impairment associated 
with adult-onset dementia disorders including Alzheimer’s disease (AD) and vascular 
dementia (VaD). 
Cholinergic transporters control cellular mechanisms of acetylcholine (ACh) synthe-
sis and release at presynaptic terminals. The high-affinity choline uptake transporter 
(CHT) recaptures choline deriving from acetylcholine (ACh) hydrolysis by acetylcho-
linesterase (AChE). Choline is resynthesized into ACh by choline acetyltransferase. 
The neurotransmitter is loaded into synaptic vesicles by the vesicular ACh transporter 
(VAChT). Abnormal regulation of cholinergic transporters might contribute to the cog-
nitive impairments associated with neurodegenerative disorders.
This study has assessed the influence of 4 week treatment with the AChE/cholineste-
rase (ChE) with the AChE inhibitor galantamine or with the cholinergic precursor 
choline alphoscerate (alpha-glyceryl-phosphorylcholine, GPC) on spontaneously hy-
pertensive rats (SHR) used as a model of cerebrovascular injury. In these rats an obvi-
ous cholinergic hypofunction is noticeable. They could therefore represent a model for 
investigating the effect of drugs on cholinergic system. Wistar Kyoto (WKY) rats which 
belong from the normotensive phenotype opposed to SHR were investigated as well. 
Analysis performed by immunochemistry and ELISA included frontal cortex, striatum, 
hippocampus and peripheral blood lymphocytes (PBL). 
An increased expression of CHT and VAChT was observed in brain areas investi-
gated and in PBL of SHR. This increase probably represents an up-regulation to coun-
ter cholinergic deficit of SHR. Treatment with galantamine countered the increase of 
CHT and VAChT. Treatment with GPC further increased CHT and to a greater extent 
VAChT. 
The effect of GFC is consistent with an increased synthesis of ACh it induces. This 
suggest that association between GPC and AChE/ChE inhibitors may represent a strat-
egy worthwhile of being investigated in appropriate clinical trials. 
Key words
Cholinergic enhancing drugs, vesicular acetylcholine transporter, choline uptake transporter, 
brain damage
